Validation of an HPLC–UV Method for Quantifying Oncocalyxone A in Different Media and Nanocapsules
- 59 Downloads
Oncocalyxone A (onco A) isolated from heartwood of Cordia oncocalyx (Auxemma oncocalyx), exhibits antitumor, analgesic and anti-inflammatory activities. In order to produce drug delivery systems containing onco A, the objective of this study was to develop and validate an HPLC method for quantifying onco A in different media and nanocapsules. The validation method was performed according to ICH guidelines for pharmaceutical products. The solubility of onco A was determined in deionized water, simulated gastric and intestinal fluids, buffer solutions at pH 5.5, 7.0, 9.0 and oils: copaiba, soybean and medium-chain triglycerides. The partition coefficients of onco A between n-octanol, oils and aqueous phase were determined at 25 °C. Accuracy, intra- and inter-day precision values presented low random errors (less than or equal to 2.53, 2.21 and 3.12%, respectively). Onco A solubility was greater in water, buffer solutions, and simulated gastric and intestinal fluids (817 ± 54 μg mL−1) than in oils (434 ± 25 μg mL−1). Onco A showed hydrophilic characteristics (log P < 1). The onco A content in chitosan-coated nanoparticles was 99.6% (995.8 ± 26.5 μg mL−1). In conclusion, a robust HPLC method for quantifying onco A was successfully developed, validated and applied for determining onco A solubility in different pHs, partition coefficient and nanocapsules.
KeywordsCordia oncocalyx Oncocalyxone A Nanocapsules Partition coefficient Solubility
The authors thank the Brazilian research agencies for their financial support: Brazilian Ministry of Education (CAPES, PNPD-PPGNANOFARMA), Brazilian Council for Research and Development (CNPq, Grant #311232/2013-2), Brazilian Ministry of Science and Technology (MCTI), Laboratórios Associados em Nanotecnologia-UFPE (LARnano/SisNANO-MCTI, Grant # 402282/2013-2).
Compliance with Ethical Standards
Conflict of interest
The authors declare no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 5.Ilayaraja S, Prabakaran K, Manivannan R (2014) Evaluation of anti-bacterial, analgesic and anti-inflammatory activities of Oncocalyxone A isolated from Prenanthes sarmentosus. J Appl Pharm Sci 4:88–91Google Scholar
- 6.Sivagnanam I, Kalaivanam P, Rajamanickam M (2013) Antibiabetic activity of oncocalyxone A isolated from Prenanthes sarmenthosus. Int J Pharm Sci 5:630–633Google Scholar
- 7.Levya A, Pessoa C, Boogaerdt F, Sokaroski R, Lemos TL, Weltmore LA, Hurura RR, Moraes MO (2000) Oncocalyxones A and C, 1,4-anthracenediones from Auxemma oncocalyx: comparison with anticancer 1,9-anthracenediones. Anticancer Res 20:1029–1032Google Scholar
- 11.Costa JGM, Arriaga AM, Mattos CMC, Pessoa ODL, Nascimento Lemos TLG (2004) High-performance liquid chromatographic analysis of bioactive quinones from Auxemma glazioviana. Arkivoc 6:72–79Google Scholar
- 12.International Conference on Harmonization (ICH) (2005) Q2 (R1): validation of analytical procedures: text and methodology, November 2005. https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf. Accessed 14 Mar 2019
- 13.Food and Drug Administration (FDA) (2015) Analytical procedures and methods validation for drugs and biologics: guidance for industry, 2015. https://www.fda.gov/downloads/drugs/guidances/ucm386366.pdf. Accessed 14 Mar 2019
- 14.Agência Nacional de Vigilância Sanitária (ANVISA) RDC N°166-24 July 2017. http://portal.anvisa.gov.br/documents/10181/2721567/RDC_166_2017_COMP.pdf/d5fb92b3-6c6b-4130-8670-4e3263763401. Accessed 14 Mar 2019
- 17.Barreto ACH, Santiago VR, Freire RM, Mazetto SE, Denardin JC, Mele G, Cavalvante IM, Ribeiro MENP, Ricardo NMPS, Gonçalves T, Carboni L, Lemos TLG, Pessoa ODL, Fechine PBA (2013) Magnetic nanosystem for cancer therapy using oncocalyxone A, an antitumor secondary metabolite isolated from a Brazilian plant. Int J Mol Sci 14:18269–18283CrossRefGoogle Scholar
- 18.United States of Pharmacopoeia (USP) (2016) 39th edition, Rockville. https://www.uspnf.com. Accessed 14 Mar 2019
- 26.Mcnair H, Polite LN (2007) 17 Troubleshooting in high performance liquid chromatography. Sep Sci Technol 8:459–477Google Scholar